

COVER PAGE

FAST STUDY (NCT04231409)

Study to Demonstrate the Value of Fast-Acting Subperception (FAST) using the Spectra WaveWriter™
Spinal Cord Stimulator System in the Treatment of Chronic Pain (A4070)

This serves as a cover page for the FAST Study – A Sub-study of COMBO Study (NCT03689920)

Version E (Current Version): 31 Jan 2020

Sponsored By

Boston Scientific Neuromodulation Corporation

25155 Rye Canyon Loop

Valencia, CA 91355

United States of America

**Study to Demonstrate the Value of Fast-Acting Subperception (FAST)
using the Spectra WaveWriter™ Spinal Cord Stimulator System in the
Treatment of Chronic Pain**

FAST Study

COMBO Sub-Study

A4070

CLINICAL INVESTIGATION PLAN

NCT03689920

Sponsored By

Boston Scientific Neuromodulation Corporation

25155 Rye Canyon Loop

Valencia, CA 91355

United States of America

This protocol contains confidential information for use by the Investigators and their designated representatives participating in this clinical investigation. The protocol should be held confidential and maintained in a secure location.

Do not copy or distribute without written permission from Boston Scientific Corporation.

Contact Information

Role	Contact
Clinical Contact	<p>Natalie Bloom Lyons Director, U.S. Clinical Operations Boston Scientific Neuromodulation Corporation 25155 Rye Canyon Loop Valencia, CA 91355 Telephone: (763) 228-9040 Fax: (661) 949-4592 Email: natalie.bloomlyons@bsci.com</p> <p>Roshini Jain Director, Clinical Sciences and Scientific Communications Clinical Research Department Boston Scientific Neuromodulation 25155 Rye Canyon Loop Valencia, CA 91355 USA Telephone: (661) 949-4350 Fax: (661) 949-4592 Email: Roshini.jain@bsci.com</p>
Coordinating Principal Investigator	Mark S. Wallace, M.D. University of California San Diego Medical Center 9300 Campus Point Dr La Jolla, CA 92037 United States

2. Protocol Synopsis

FAST Study A Study to Demonstrate the Value of Fast-Acting Subperception (FAST) using the Spectra WaveWriter™ Spinal Cord Stimulator System in the Treatment of Chronic Pain	
Primary Objective	To evaluate the effectiveness of Spinal Cord Stimulation (SCS) with fast-acting subperception (FAST) as compared to subperception SCS in patients with chronic pain when using the Boston Scientific Spectra WaveWriter SCS System.
Secondary Objectives	To determine the impact of Spectra WaveWriter SCS System on global patient outcomes including quality of life, patient preference, etc.
Indication(s) for Use	The Spectra WaveWriter Spinal Cord Stimulator (SCS) System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain.
Commercial Device/System	BSC Spectra WaveWriter™ SCS System
Study Design	Prospective, multi-center, parallel-group randomized controlled trial with an adaptive design
Planned Number of Subjects	[REDACTED]
Planned Number of Sites / Countries	[REDACTED]

FAST Study

A Study to Demonstrate the Value of Fast-Acting Subperception (FAST) using the Spectra WaveWriter™ Spinal Cord Stimulator System in the Treatment of Chronic Pain

Safety Parameters	Rates of occurrence of all device hardware, device stimulation and procedure related non-serious adverse events, all serious adverse events, and unanticipated adverse events through the end of the study.
Primary Effectiveness Endpoint	Proportion of subjects with 50% or greater reduction from Baseline Visit in average overall pain intensity at 3 months post-randomization, with no increase in baseline average daily opioid medications used to treat pain.
Secondary Effectiveness Endpoint	       
Exploratory Endpoints	

FAST Study

A Study to Demonstrate the Value of Fast-Acting Subperception (FAST) using the Spectra WaveWriter™ Spinal Cord Stimulator System in the Treatment of Chronic Pain

A series of 15 horizontal black bars of varying lengths, decreasing from left to right. The bars are evenly spaced and set against a white background. The lengths of the bars decrease in a regular, linear fashion from the first bar on the left to the last bar on the right.

FAST Study

A Study to Demonstrate the Value of Fast-Acting Subperception (FAST) using the Spectra WaveWriter™ Spinal Cord Stimulator System in the Treatment of Chronic Pain

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>
Follow-up Schedule	<p>Study events occur at the following time points:</p> <ul style="list-style-type: none">• Screening• Opioid Medication Lock Visit (Up to 35 days following Informed Consent)• Baseline Period (14 days)• Baseline Visit (0 - 7 days post Baseline Period)• Implant Procedures (up to 90 days post Baseline Visit)• Healing Period (0 - 28 days)• Randomization Visit (Day 0)• Programming Lock Visit (70 - 14 days post-randomization Visit)• 3 Month Visit (90 + 14 days post-randomization Visit)• 6-Month Visit (180 ± 30 days post-randomization Visit)• 9-Month Visit (270 ± 30 days post-randomization Visit)• Year 1 Visit (365 ± 30 days post-randomization Visit)• Year 2 Visit (730 ± 30 days post-randomization Visit)
Study Duration	<p>[REDACTED]</p> <p>[REDACTED]</p>
Participant Duration	<p>[REDACTED]</p>
Inclusion Criteria	IC1. Chronic pain of the trunk and/or limbs for at least 6 months with back pain greater or equal to leg pain.

FAST Study

A Study to Demonstrate the Value of Fast-Acting Subperception (FAST) using the Spectra WaveWriter™ Spinal Cord Stimulator System in the Treatment of Chronic Pain

	<p>IC3. No back surgery within 6 months prior to Screening</p> <p>IC9. 22 years of age or older when written informed consent is obtained</p> <p>IC11. Able to independently read and complete all questionnaires and assessments provided in English</p> <p>IC13. Subject signed a valid, IRB-approved informed consent form (ICF) provided in English</p>
Exclusion Criteria	

FAST Study

A Study to Demonstrate the Value of Fast-Acting Subperception (FAST) using the Spectra WaveWriter™ Spinal Cord Stimulator System in the Treatment of Chronic Pain

EC7. Any pain-related diagnosis or medical/psychological condition that, in the clinician's best judgment, might confound reporting of study outcomes (e.g. pelvic pain, anginal pain, chronic migraine, brain or spinal cord tumor)

EC15. Significant cognitive impairment at Screening that, in the opinion of the Investigator, would reasonably be expected to impair the study candidate's ability to participate in the study

Participating (or intends to participate) in another drug or device

FAST Study

A Study to Demonstrate the Value of Fast-Acting Subperception (FAST) using the Spectra WaveWriter™ Spinal Cord Stimulator System in the Treatment of Chronic Pain


	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>EC23. [REDACTED]</p>
--	---

Statistical Methods


Primary Statistical Hypothesis	<p>The primary statistical hypothesis in this study is that the proportion of subjects with 50% or greater reduction from Baseline Visit in average daily overall pain intensity at 3 months post randomization in the FAST group is non-inferior compared to the Control (i.e. subperception) group</p> $H_0: \pi_t - \pi_c \leq -0.20$ $H_1: \pi_t - \pi_c > -0.20$ <p>Where π_t and π_c are the proportion of subjects with 50% or greater reduction from Baseline in average daily overall pain intensity at 3 months post randomization with no increase in baseline average daily opioid pain medications using FAST and subperception settings, respectively. The study's non-inferiority margin is 0.20.</p>
Statistical Test Method	[REDACTED]


FAST Study

A Study to Demonstrate the Value of Fast-Acting Subperception (FAST) using the Spectra WaveWriter™ Spinal Cord Stimulator System in the Treatment of Chronic Pain


Sample Size Parameters	
Interim Analysis	

STUDY SCHEMATIC









4. Introduction

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

5. Commercial Device Description (part of Standard of Care)

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

6. Study Objectives and Endpoints

6.1. *Primary Objective*

The primary objective of this study is to evaluate the effectiveness of Spinal Cord Stimulation (SCS) with fast-acting subperception (FAST) as compared to subperception SCS in patients with chronic pain when using the Boston Scientific Spectra WaveWriter SCS System.

6.2. *Secondary Objective*

The secondary objective of this study is to determine the impact of Spectra WaveWriter SCS System on global patient outcomes including quality of life, patient preference, etc.

6.3. *Primary Endpoint*

The primary endpoint is the proportion of subjects with 50% or greater reduction from the Baseline Visit in average overall pain intensity at 3 months post randomization, with no increase in baseline average daily opioid medications used to treat pain.

6.4. *Secondary Endpoints*





6.6. Safety Parameters

Safety parameters include the rates of occurrence of all device hardware, device stimulation and procedure related non-serious adverse events, all serious adverse events, and unanticipated adverse events through the end of the study.


7. Study Design

The study is a prospective, multi-center, parallel group randomized controlled trial with an adaptive design. All participants will receive the Spectra WaveWriter Spinal Cord Stimulator (SCS) system and followed per the study schedule as shown in study schematic Figure 7.1-1.

7.1. Scale and Duration



Figure 7.1-1: FAST Study Design



7.2. *Treatment Assignment*

All enrolled subjects who pass eligibility criteria will receive a trial. Subjects with a positive trial will proceed to receive permanent implant. Following permanent implant, all subjects' device will be randomized in a 1:1 ratio to either receive:

- WaveWriter Settings: Fast-acting subperception (FAST)
- Conventional Settings: Subperception

7.3. *Justification for the Study Design*

The study is a prospective, multi-center, parallel group randomized controlled trial with an adaptive design. The study is designed to demonstrate the value of fast-acting subperception for sustained clinically significant pain relief in patients with chronic pain when using the Boston Scientific Spectra WaveWriter SCS System. Additionally, the impact of the Spectra WaveWriter SCS System on global patient outcomes, quality of life and patient preference will also be evaluated.

A prospective study design will eliminate the bias associated with case selection in a retrospective review and will ensure that identical procedures are followed for data capture and review.

A multi-center design will minimize the impact on treatment outcome that may potentially result from differences in patient selection, regional differences in the patient demographic, and differences in investigator technique and patient management.

The study design includes two groups (arms) – WaveWriter group and Conventional group. The WaveWriter group will receive fast-acting subperception (FAST) as available in the WaveWriter SCS System while the conventional group will receive subperception programming. The Conventional group will serve as a control in this study. Randomization (1:1) will minimize selection bias and impact of demographic variables.

The primary endpoint is the proportion of subjects with 50% or greater reduction (responder rate) from the Baseline Visit in average overall pain intensity at 3 months post-randomization, with no increase in baseline average daily opioid medications used to treat pain. A 3-month endpoint was chosen as 3 months provides adequate time for a subject to have their programming parameters optimized.

8. Subject Selection

8.1. Study Population and Eligibility

Study candidates will be drawn from the population of patient's resident in pain management or surgical medical practices. The study eligibility criteria are listed below.

8.2. Inclusion Criteria

Subjects who meet all of the following criteria (see Table 8.2-1) may be given consideration for inclusion in this clinical investigation, provided no exclusion criterion (see Section 8.3-1) is met.

Table 8.2-1: Inclusion Criteria

Clinical Inclusion Criteria	IC1. Chronic pain of the trunk and/or limbs for at least 6 months with back pain greater or equal to leg pain.

8.3. *Exclusion Criteria*

Subjects who meet any one of the following criteria cannot be included in this study or will be excluded from this clinical study.

Table 8.3- 1 Exclusion Criteria

Clinical Exclusion Criteria	
	Average leg pain intensity is greater than average low back pain
	[REDACTED]
EC7. Any pain-related diagnosis or medical/psychological condition that, in the clinician's best judgment, might confound reporting of study outcomes (e.g. pelvic pain, anginal pain, chronic migraine, brain or spinal cord tumor)	[REDACTED]
[REDACTED]	[REDACTED]
EC15. Significant cognitive impairment at Screening that, in the opinion of the Investigator, would reasonably be expected to impair the study candidate's ability to participate in the study	
EC16. Participating (or intends to participate) in another drug or device clinical trial that may influence the data that will be collected for this study	[REDACTED]
[REDACTED]	[REDACTED]
EC18. A female who is breastfeeding	
EC19. A female of childbearing potential planning to get pregnant during the course of the study or not using adequate contraception	

Figure 1 is a horizontal bar chart comparing the percentage of patients with different types of cancer across three groups: EC23, EC24, and EC25. The y-axis represents the percentage of patients (0-100), and the x-axis represents the type of cancer. The legend indicates: EC23 (dark grey), EC24 (medium grey), and EC25 (light grey). The chart shows that EC23 has the highest percentage of patients with all cancer types, followed by EC24, and then EC25.

Cancer Type	EC23 (%)	EC24 (%)	EC25 (%)
EC23	100	100	100
EC24	100	100	100
EC25	100	100	100

9. Subject Accountability

9.1. *Point of Enrollment*

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

9.2. *Withdrawal*

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

9.3. *Subject Status and Classification*

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

9.4. Enrollment Controls

1. **What is the primary purpose of the proposed legislation?**

The study will implement a formal *Enrollment Communication Plan*. The plan will outline the specific activities, as well as the nature and timing of communications to investigators in order to minimize the risk of enrollment beyond the protocol-specified enrollment caps determined by the statistical analysis plan.

9.5. *End-of-Study Action Plan*

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

10. Study Methods

10.1. *Data Collection*

The data collection schedule is shown in table below.

Table 10.1-1: Data Collection Schedule

** For unscheduled visits where procedures are performed.

*** Only when device programming is performed.

[†] The device will remain off after permanent implant until the Activation Visit.

10.2. Study Candidate Screening

Subjects' eligibility for the study will be assessed based on study Inclusion and Exclusion criteria listed in Sections 9.2 and 9.3, respectively. Subjects who have provided informed consent and who have been determined to not meet all eligibility requirements will be withdrawn.

10.3. Informed Consent

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

10.3.1. Screening Period

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

10.4. Opioid Medication Lock Visit (Up to 35 days following informed consent)

The Opioid Medication Lock Visit will occur within 35 days following informed consent. However, this visit may occur on the same day as that of the Informed consent as well following completion of consent.

At this visit, the subject's opioid pain medications will be locked, with no increase in type/dose/route/frequency, until the 3-Month post-randomization Visit.

At this visit (or during the screening period), the investigator will convert the subject's opioid medication prescriptions from PRN to a fixed dose, as needed.

10.5. Baseline Period (14 days)

The Baseline Period will last for 14 consecutive days following the Opioid Medication Lock Visit. At the end of the Baseline Period, subjects will return to the clinic for their Baseline Visit.

Subjects are to not make any increases to their opioid pain medications during this period.

10.6. Baseline Visit (0 – 7 days post Baseline Period)

At the Baseline Visit, subjects will return to the clinic to complete remaining screening requirements. Any adverse since the last study visit will be collected.

The following assessments, as outlined in Table 11.1-1, will be conducted:

- Demographics

- Medical history
- Beck Depression Inventory (BDI-II)
- Oswestry Disability Index (ODIv2.1a)
- Short Form Health Survey 36 (SF-36v2)
- EQ-5D 5-Level
- Pain Intensity: VRS
- Pain Intensity: NRS
- Pittsburg Sleep Quality Index (PSQI)

Subjects that meet all study criteria will be scheduled for the device implant procedures (trial and permanent implant of the SCS system). If a subject fails to meet all the eligibility criteria, they will be withdrawn from the study.

End of Visit Information:

- Subjects should be reminded not to make any increases to their opioid medications.

10.7. Implant Procedures (Up to 90 days following the Baseline Visit)

Subjects will have up to 90 days following the Baseline Visit to receive their Spectra WaveWriter System. Subjects will undergo a trial procedure per standard of care. Following a successful trial, i.e. at least 50% pain reduction in their overall pain as compared with Baseline, the subject will proceed to permanent implantation. Subjects with an unsuccessful implant procedure will be followed for 2 weeks for procedure related adverse events then withdrawn from the study. Acute opioid pain medications may be taken.

10.8. Healing Period (0 - 28 days following Implant Procedures)

The subject's device will remain inactivated (device OFF) for up to 28 days following the permanent implantation procedure to allow for healing. Acute opioid pain medications may be taken during this period. No additional scheduled assessments will be completed during this period.

For those subjects receiving the surgical (paddle) lead, it is recommended that their device remain inactivated (device OFF) as part of healing for 21-28 days.

10.9. Randomization Visit (Day 0)

At the Randomization Visit, subjects will be randomized in a 1:1 ratio to either receive

- WaveWriter Settings: Fast-acting subperception
- Conventional Settings: Subperception

Subjects will receive their assigned treatment settings up to 3 Mo. Visit. Any protocol required adverse events since the last study visit will be collected.

The Activation Questionnaire must be completed prior to and post-activation to document pain scores, time taken, etc.

Subjects must stop taking acute opioid pain medications, as applicable, and are not to increase their opioid pain medications up to the 3-Month Visit.

Information regarding programming parameters will be collected. To aid in programming it is recommended that thoracic and/or lumbar imaging is obtained at this visit or up to 7 days prior to the visit to show the position(s) of the study device lead(s). In the event of suspected lead migration, imaging may be performed to document lead positions.

End of Visit Information:

- Subjects will receive instructions on the use of the device including the Remote Control and charging system.
- Subjects are to contact the site in an event that any additional intervention is warranted, to report a complaint and/or a suspected adverse event, reprogramming, etc.
- Subjects should be reminded not to make any increase in their opioid pain medications.

10.10. Programming Lock Visit (Day 70 - 14 days post randomization Visit)

At the Programming Lock Visit, subjects will return to the clinic to have their programs locked. Any protocol required adverse events since the last study visit will be collected.

No further changes to the subject's programs (for e.g. electrode configuration) will be allowed except to resolve a device and/or stimulation-related AE.

Information regarding programming parameters and device information may be collected.

End of Visit Information:

- Subjects will receive instructions on the use of the device including the Remote Control and charging system, as needed.
- Subjects are to contact the site in an event that any additional intervention is warranted, to report a complaint and/or a suspected adverse event, reprogramming, etc.
- Subjects should be reminded not to make any increase in their opioid medications.

10.11. 3-Month Visit (90 + 14 days post randomization Visit)

During the 3-Month Visit, subjects will return to the clinic for study evaluations and programming. Any protocol required adverse events since their last study visit will be collected.

The following assessments will be completed as summarized in Table 11.1-1:

- Beck Depression Inventory (BDI-II)
- Oswestry Disability Index version 2.1a (ODI v2.1a)
- Short Form Health Survey 36 items (SF-36 v2)

- EQ-5D 5-Level
- Pain Intensity: VRS
- Pain Intensity: NRS
- Clinical Global Impression of Change (CGI-C)
- Patient Global Impression of Change (PGI-C)
- Percent Pain Relief (PPR)
- Pittsburgh Sleep Quality Index (PSQI)
- Treatment Satisfaction Questionnaire for Medication - modified (TSQM-9m)

Following completion of assessments, subjects' device will be programmed as needed and programming information may be collected. At this visit, all subjects may receive programming as available on the device with no restrictions. .

- In the event of suspected lead migration or to aid programming the subject's device, imaging may be performed to document lead position.
- Any additional instructions related to charging of the device and/or use of Remote Control may be provided.

End of Visit Information:

- Subjects will receive instructions on the use of the device including the Remote Control and charging system, as needed.
- Subjects are to contact the site in an event that any additional intervention is warranted, to report a complaint and/or a suspected adverse event, reprogramming, etc.
- Subjects' opioid medications are no longer locked and can be changed, if needed for the remainder of the study

10.12. 6-Month Visit (180 ± 30 days post randomization Visit)

During the 6-Month Visit, subjects will return to the clinic for study evaluations and programming. Any protocol required adverse events since their last study visit will be collected.

The following assessments will be completed as summarized in Table 11.1-1:

- Oswestry Disability Index version 2.1a (ODI v2.1a)
- Short Form Health Survey 36 items (SF-36 v2)
- EQ-5D 5-Level
- Pain Intensity: NRS
- Pain Intensity: VRS
- Clinical Global Impression of Change (CGI-C)
- Patient Global Impression of Change (PGI-C)

- Percent Pain Relief (PPR)
- Pittsburgh Sleep Quality Index (PSQI)
- Preference Questionnaire
- Treatment Satisfaction Questionnaire for Medication - modified (TSQM-9m)

Following completion of assessments, subjects' device will be programmed as needed and programming information may be collected.

- In the event of suspected lead migration or to aid programming the subject's device, imaging may be performed to document lead position.
- Any additional instructions related to charging of the device and/or use of Remote Control may be provided.

End of Visit Information:

- Subjects will receive instructions on the use of the device including the Remote Control and charging system, as needed.
- Subjects are to contact the site in an event that any additional intervention is warranted, to report a complaint and/or a suspected adverse event, reprogramming, etc.
- Changes to opioid pain medications are allowed up to End of Study Visit.

10.13. 9-Month Visit (270 ± 30 days post randomization Visit)

During the 9-Month Visit, subjects will return to the clinic for study evaluations and programming. Any protocol required adverse events since their last study visit will be collected.

The following assessments will be completed as summarized in Table 11.1-1:

- Oswestry Disability Index version 2.1a (ODI v2.1a)
- Short Form Health Survey 36 items (SF-36 v2)
- EQ-5D 5-Level
- Pain Intensity: NRS
- Pain Intensity: VRS
- Clinical Global Impression of Change (CGI-C)
- Patient Global Impression of Change (PGI-C)
- Percent Pain Relief (PPR)
- Pittsburgh Sleep Quality Index (PSQI)
- Preference Questionnaire
- Treatment Satisfaction Questionnaire for Medication - modified (TSQM-9m)

Following completion of assessments, subjects' device will be programmed as needed and programming information may be collected.

- In the event of suspected lead migration or to aid programming the subject's device, imaging may be performed to document lead position.
- Any additional instructions related to charging of the device and/or use of Remote Control may be provided.

End of Visit Information:

- Subjects will receive instructions on the use of the device including the Remote Control and charging system, as needed.
- Subjects are to contact the site in an event that any additional intervention is warranted, to report a complaint and/or a suspected adverse event, reprogramming, etc.

10.14. Year 1 and Year 2 Visit (365 ± 30 days post randomization Visit and 730 ± 30 days post-randomization Visit)

During the 1 and 2 Year Visits, subjects will return to the clinic for study evaluations and programming. Any protocol required adverse events since their last study visit will be collected.

The following assessments will be completed as summarized in Table 11.1-1:

- Beck Depression Inventory (BDI-II)
- Oswestry Disability Index version 2.1a (ODI v2.1a)
- Short Form Health Survey 36 items (SF-36 v2)
- EQ-5D 5-Level
- Pain Intensity: NRS
- Pain Intensity: VRS
- Clinical Global Impression of Change (CGI-C)
- Patient Global Impression of Change (PGI-C)
- Percent Pain Relief (PPR)
- Pittsburg Sleep Quality Index (PSQI)
- Preference Questionnaire
- Treatment Satisfaction Questionnaire for Medication - modified (TSQM-9m)

Following completion of assessments, subjects' device will be programmed as needed and programming information may be collected.

- In the event of suspected lead migration or to aid programming the subject's device, imaging may be performed to document lead position.
- Any additional instructions related to charging of the device and/or use of Remote Control may be provided.

End of Visit Information:

- Subjects will receive instructions on the use of the device including the Remote Control and charging system, as needed.
- Subjects are to contact the site in an event that any additional intervention is warranted, to report a complaint and/or a suspected adverse event, reprogramming, etc.

The 2 Year Visit is the End of Study Visit and End of Study Action Plan (ESAP) will be followed as described in Section 10.5.

10.15. *Unscheduled Visit*

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

10.15.1. Revision or Replacement of Leads, Extensions and/or IPGs

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

10.15.2. Interventional Pain Procedures

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

10.16. *Medication Requirements*

Opioid Medication Lock Period (Medication Lock visit to 3-Month Visit):

Investigators/Subjects will not be allowed to increase opioid pain medications from the Medication Lock visit until completion of the 3-Month Visit.

The use of acute opioid pain medication for procedural discomfort is allowed during the Procedures and Healing Period and in the event of the revision or replacement of leads, extensions and/or IPG, per site's routine care.

Opioid Medication Open Period (3-Month Visit to End of Study visit)

Investigators/Subjects may change opioid pain medications during the pain medication open period, from the 3-Month Visit to the End of Study Visit as needed.

10.17. *Study Completion*

All randomized subjects permanently implanted will be followed through completion of the 2-Year Visit or study withdrawal. The End of Study Action Plan defines the actions to be taken when the subject reaches the end of their study participation.

10.18. *Source Documents*

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

11. Statistical Considerations

11.1. *Endpoints*

11.1.1. Primary Endpoint

The primary endpoint for this study is the proportion of subjects with 50% or greater reduction from Baseline Visit in average overall pain intensity at 3 months post randomization with no increase in baseline average opioid medications used to treat pain.

[REDACTED]

[REDACTED]

11.1.1.1. Hypotheses

The primary statistical hypothesis in this study is that the proportion of subjects with 50% or greater reduction from Baseline Visit in average daily overall pain intensity at 3 months post randomization in the FAST group is non-inferior compared to the Control (i.e. subperception) group

$$H_0: \pi_t - \pi_c \leq -0.20$$

$$H_1: \pi_t - \pi_c > -0.20$$

Where π_t and π_c are the proportion of subjects with 50% or greater reduction from Baseline in average daily overall pain intensity at 3 months post randomization with no increase in baseline average daily opioid pain medications using FAST and subperception settings, respectively. The study's non-inferiority margin is 0.20.

11.1.1.2. Sample Size

© 2013 Pearson Education, Inc.

[REDACTED]

100% of the time, the system is able to correctly identify the target class.

For more information, contact the Office of the Vice President for Research and Economic Development at 515-294-6450 or research@iastate.edu.

For more information, contact the Office of the Vice President for Research and Economic Development at 515-294-6450 or research@iastate.edu.

Digitized by srujanika@gmail.com

113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
559
560
561
562
563
564
565
566
567
568
569
569
570
571
572
573
574
575
576
577
578
579
579
580
581
582
583
584
585
586
587
588
589
589
590
591
592
593
594
595
596
597
598
599
599
600
601
602
603
604
605
606
607
608
609
609
610
611
612
613
614
615
616
617
618
619
619
620
621
622
623
624
625
626
627
628
629
629
630
631
632
633
634
635
636
637
638
639
639
640
641
642
643
644
645
646
647
648
649
649
650
651
652
653
654
655
656
657
658
659
659
660
661
662
663
664
665
666
667
668
669
669
670
671
672
673
674
675
676
677
678
679
679
680
681
682
683
684
685
686
687
688
689
689
690
691
692
693
694
695
696
697
698
699
699
700
701
702
703
704
705
706
707
708
709
709
710
711
712
713
714
715
716
717
718
719
719
720
721
722
723
724
725
726
727
728
729
729
730
731
732
733
734
735
736
737
738
739
739
740
741
742
743
744
745
746
747
748
749
749
750
751
752
753
754
755
756
757
758
759
759
760
761
762
763
764
765
766
767
768
769
769
770
771
772
773
774
775
776
777
778
779
779
780
781
782
783
784
785
786
787
788
789
789
790
791
792
793
794
795
796
797
798
799
799
800
801
802
803
804
805
806
807
808
809
809
810
811
812
813
814
815
816
817
818
819
819
820
821
822
823
824
825
826
827
828
829
829
830
831
832
833
834
835
836
837
838
839
839
840
841
842
843
844
845
846
847
848
849
849
850
851
852
853
854
855
856
857
858
859
859
860
861
862
863
864
865
866
867
868
869
869
870
871
872
873
874
875
876
877
878
879
879
880
881
882
883
884
885
886
887
888
889
889
890
891
892
893
894
895
896
897
898
899
899
900
901
902
903
904
905
906
907
908
909
909
910
911
912
913
914
915
916
917
918
919
919
920
921
922
923
924
925
926
927
928
929
929
930
931
932
933
934
935
936
937
938
939
939
940
941
942
943
944
945
946
947
948
949
949
950
951
952
953
954
955
956
957
958
959
959
960
961
962
963
964
965
966
967
968
969
969
970
971
972
973
974
975
976
977
978
979
979
980
981
982
983
984
985
986
987
988
989
989
990
991
992
993
994
995
996
997
998
999
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2159
2160
2161
2162
2163
2164
2165
2166

For more information, contact the Office of the Vice President for Research and Economic Development at 319-335-1111 or research@uiowa.edu.

11. **What is the primary purpose of the *Journal of Clinical Endocrinology and Metabolism*?**

© 2019 Pearson Education, Inc.

© 2013 Pearson Education, Inc.

1. **What is the primary purpose of the study?** (Please check one box)

© 2010 by the author; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).

Digitized by srujanika@gmail.com

1. **What is the primary purpose of the study?** (Please select one)

For more information, contact the Office of the Vice President for Research and Economic Development at 319-335-1111 or research@uiowa.edu.

© 2013 Pearson Education, Inc.

Digitized by srujanika@gmail.com

© 2013 Pearson Education, Inc.

11. *What is the primary purpose of the following statement?*

© 2013 Pearson Education, Inc.

For more information, contact the Office of the Vice President for Research and Economic Development at 319-273-2500 or research@uiowa.edu.

11. **What is the primary purpose of the *Journal of Clinical Endocrinology and Metabolism*?**

www.ijerph.com | ISSN: 1660-4601 | DOI: 10.3390/ijerph16030890 | 890

11.2. General Statistical Methods

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

12. Data Management

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

12.1. Data Collection, Processing, and Review

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document

12.2. Study Assessments

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

12.2.1. Activation Questionnaire

The Activation Questionnaire is administered by site personnel at the activation/randomization visit and will collect information related to subject's overall improvement in pain scores, time taken to achieve pain relief, etc.

12.3. Data Retention

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document

13. Deviations

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

14. Compliance

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

15. Monitoring

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

16. Potential Risks and Benefits

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

17. Safety Reporting

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

18. Informed Consent

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

19. Committees

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

19.1. *Safety Monitoring Process*

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

20. Suspension or Termination

20.1 This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

21. Publication Policy

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

22. Bibliography

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

23. Abbreviations and Definitions

23.1. Abbreviations

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.

New abbreviations shown below.

Table 23.1-1: Abbreviations

Abbreviation/Acronym	Term
FAST	Fast Acting Subperception

23.2. Definitions

This is an appendix to the COMBO Study and only contains information that is unique to this sub-study.

Information that is common to both is not repeated in this document.